Stoke Therapeutics (STOK) Cash from Operations Growth (3y) (2021 - 2026)
Stoke Therapeutics (STOK) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 34.32% |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.51 Bn | - | -41.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.56% |
| Dec 31, 2025 | -10.83% |
| Sep 30, 2025 | -11.25% |
| Jun 30, 2025 | -8.45% |
| Mar 31, 2025 | 59.50% |
| Dec 31, 2024 | -12.57% |
| Sep 30, 2024 | -13.76% |
| Jun 30, 2024 | -3.35% |
| Mar 31, 2024 | -6.85% |
| Dec 31, 2023 | -23.62% |
| Sep 30, 2023 | -16.66% |
| Jun 30, 2023 | -31.23% |
| Mar 31, 2023 | -25.63% |
| Dec 31, 2022 | -29.93% |
| Sep 30, 2022 | -39.94% |
| Jun 30, 2022 | -47.00% |
| Mar 31, 2022 | 91.06% |
| Dec 31, 2021 | -66.61% |
| Sep 30, 2021 | -69.01% |